A股重磅！科创成长层，要上新！

Group 1 - He Yuan Bio is officially launching its issuance process, becoming the first company to initiate this step in the new registration of the Sci-Tech Innovation Board's growth tier [1][4][6] - The company has developed a globally innovative "rice-derived blood" technology, which has received support from the national "Major New Drug Creation" program [7] - He Yuan Bio's recombinant human albumin injection (from rice) has been approved for market release, addressing China's long-standing reliance on imported human serum albumin [7] Group 2 - The issuance of new registered enterprises in the Sci-Tech Innovation Board's growth tier is progressing steadily, with the technical systems of the Shanghai Stock Exchange having completed testing [11][12] - Since the announcement of the "1+6" reform policy in June, 15 companies have applied for IPOs, including four unprofitable enterprises [9] - The Shanghai Stock Exchange has implemented various measures to enhance market attractiveness and inclusivity, supporting the development of technological innovation and new productive forces [14]